Last reviewed · How we verify

NCT06908785: CIR-ROTEM

Utility of ROTEM® for Risk Stratification of Post-Invasive Procedure Hemorrhage in Patients With Cirrhosis (CIR-ROTEM)

Recruiting now Last updated 3 April 2025
What this trial tests

trial testing Rotational thromboelastometry in Cirrhosis, Liver in 330 participants. Currently enrolling.

Timeline
1 March 2025
Primary endpoint
1 February 2028
1 September 2028

Quick facts

Lead sponsorInstituto de Investigación Marqués de Valdecilla
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment330
Start date1 March 2025
Primary completion1 February 2028
Estimated completion1 September 2028
Sites11 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Instituto de Investigación Marqués de Valdecilla — full company profile →

Who can join

Adults 18 to 65, any sex, with Cirrhosis, Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The assessment of post-procedural bleeding risk in cirrhosis remains a clinical challenge due to the lack of precise predictive tools and its high associated mortality. Although guidelines recommend a restrictive transfusion policy, adherence remains low, with a high rate of prophylactic transfusions despite unclear benefits. This multicenter, prospective, and observational study will evaluate the utility of ROTEM in bleeding risk stratification for cirrhotic patients with significant abnormalities in conventional hemostasis tests undergoing high-risk invasive procedures. The primary objective is to establish cut-off values with a high negative predictive value, optimizing transfusion decisions and reducing unnecessary blood product use. Additionally, the study will analyze the relationship between ROTEM, inflammation biomarkers, and coagulation factors, along with a cost-effectiveness analysis comparing different transfusion strategies. This will be the largest study to date assessing ROTEM in this setting, overcoming the limitations of previous studies, which have been mostly retrospective with heterogeneous populations and procedures. Its findings could contribute to the standardization of transfusion management in cirrhosis and improve healthcare resource efficiency. The widespread availability of ROTEM in other disciplines within the National Health System will facilitate its implementation in this clinical setting without requiring additional investment in equipment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Rotational thromboelastometry

Trials testing the same drug.

Other recruiting trials for Cirrhosis, Liver

Currently open trials in the same condition.

Other Instituto de Investigación Marqués de Valdecilla trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06908785.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing